Ohsfeldt Robert L, Gandhi Sanjay K, Fox Kathleen M, McKenney James M
Texas A&M Health Science Center, College Station, TX 77843-1266, USA.
Value Health. 2008 Dec;11(7):1061-9. doi: 10.1111/j.1524-4733.2008.00354.x. Epub 2008 May 16.
To compare the effectiveness and cost-effectiveness among generic and branded statins in routine clinical practice.
Retrospective database study of patients, 18+, who were newly prescribed statin therapy. Statin effectiveness and cost-effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) and attaining LDL-C goals were evaluated.
Of 10,421 eligible patients, % LDL-C reduction was significantly greater (P < 0.001) with rosuvastatin (-31.6%) than other statins (-13.9 to -21.9%). Percentage of patients at moderate/high risk attaining LDL-C goal was higher (P < 0.001) for rosuvastatin (76.1%) versus other statins (57.6-72.6%). Rosuvastatin was more effective and less costly than atorvastatin. Among generic statins, simvastatin required >61% discount to branded price to achieve similar cost-effectiveness as generic lovastatin.
In clinical practice, rosuvastatin is more effective and less costly in lowering LDL-C and LDL-C goal attainment compared with atorvastatin. Simvastatin was more cost-effective compared with lovastatin if >61% discount to branded price was achieved.
比较在常规临床实践中，通用型他汀类药物和品牌他汀类药物的有效性和成本效益。
对年龄在18岁及以上、新接受他汀类药物治疗的患者进行回顾性数据库研究。评估了他汀类药物在降低低密度脂蛋白胆固醇（LDL-C）和实现LDL-C目标方面的有效性和成本效益。
在10421名符合条件的患者中，瑞舒伐他汀使LDL-C降低的百分比（-31.6%）显著高于其他他汀类药物（-13.9%至-21.9%）（P < 0.001）。中度/高危患者实现LDL-C目标的百分比，瑞舒伐他汀（76.1%）高于其他他汀类药物（57.6% - 72.6%）（P < 0.001）。瑞舒伐他汀比阿托伐他汀更有效且成本更低。在通用型他汀类药物中，辛伐他汀需要比品牌药价格低>61%才能达到与通用型洛伐他汀相似的成本效益。
在临床实践中，与阿托伐他汀相比，瑞舒伐他汀在降低LDL-C和实现LDL-C目标方面更有效且成本更低。如果辛伐他汀比品牌药价格低>61%，则其与洛伐他汀相比更具成本效益。
